Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: goldsachstrader who wrote (8414)	12/3/2009 12:21:32 PM
From: willy61	1 Recommendation Read Replies (1) \| Respond to of 63332

<< they said have lots of analysts(people) asking for info, but most analysts want the Full data on emab trial before they say anything. >> If this is true then we can probably not expect real coverage until June when UCB announces these results. Makes the non acceptance into ACR a much bigger negative for IMMU with regard to the short term idea of taking the power away from the shorts. Upside probably limited now to 4 - 4.5 even with positive PAM 4 stuff in January. UCB really did a job on IMMU in not allowing the full set of data to be released . Don't think the ARS will be a problem so money doesnt become a big issue right away. News out of this December conference might give a boost to 4 and unless there is coverage stock will have a tough time around there. Very disappointed that they would even make such a comment regarding analyst coverage(if they did) but it really feeds the shorts a bit , not to bright to make that kind of statement.Could have left it at we are seeing lots of interest.

To: goldsachstrader who wrote (8414)	12/3/2009 12:43:14 PM
From: me otter	Respond to of 63332

I found the ARS comment strange. Either they expect a resumption of the ARS auction process, a pay back by BAC, or that some buyer who wants what they have will emerge. My best hope was they would prevail in litigation with BAC, but I fear that their confidence in the other outcomes is misplaced.